by Written on behalf of Wise Health Law February 22, 2018 3 min read

With last year's introduction of the Health Sector Payment Transparency Act (HSPTA), which is part of Strengthening Quality and Accountability for Patients Act, 2017, (SQAPA), Ontario became the first province or territory in Canada that requires the medical industry, including medical device manufacturers and pharmaceutical companies, to disclose payments made to healthcare professionals and organizations. The goal of the legislation is to increase oversight and enable patients to make more informed decisions about their health care. This week, the Ministry of Health and Long Term Care released draft regulations that lay out how the province’s health-sector transparency legislation will work in practice. The proposed regulations include a very broad scope of individuals and organizations that fall under the umbrella of “recipients”, including regulated health professionals, their colleges, and their associations. However, the onus for reporting any transfers of value remains on the payors (i.e. the drug and devices makers), not the recipients.

New Proposed Regulations

The proposed regulations lay the groundwork needed to implement the reporting scheme envisioned by the HSPTA. The regulations seek to:
  • Specify the groups of individuals and categories of organizations that are considered “recipients” under the HSPTA;
  • Define “transfer of value” and “intermediary”
  • Add community pharmacies and laboratories to the list of payors;
  • Establish exemptions to the reporting requirements;
  • Establish the monetary threshold for reporting;
  • Establish the information, manner, and frequency of reporting;
  • Outline the process for requesting corrections of posted information.
Some of the key proposals are outlined in more detail, below.

Recipients

Under the HSPTA, financial relationships between “payors” (i.e. entities within the medical industry, including drug and medical device companies) and “recipients” (i.e. health care providers). The draft regulations propose a list of individuals and organizations that should fall under the definition of “recipients” under the Act including:
  • Health regulatory colleges;
  • Members of a health regulatory college;
  • Licensed long-term care homes;
  • Hospitals or psychiatric facilities;
  • Associations that advocate for the interest of health care professionals;
  • A person fulfilling the requirements to become a member of a regulated health profession;
  • Universities, colleges, and post-secondary institutions;
  • And others.

Transfer of Value

The HSPTA defines a transfer of value (TOV) as a “transfer of value of any kind an includes a payment, benefit, gift, advantage, perquisite or any other prescribed benefit”. The proposed regulations seek to clarify what a transfer of value entails, and proposes including the following under the definition:
  • Cash or cash equivalents;
  • Compensation for services, including speaking fees or consultant fees;
  • Event sponsorships;
  • Membership fees;
  • Facility or rental fees;
  • Entertainment, social, and sporting events;
  • Food and beverages;
  • Travel and accommodation;
  • Referral fees;
  • Charitable contributions;
  • And others.

Exemptions

The regulations propose exemptions to the reporting requirements laid out in the HSPTA.Under the regulations, payors would not be required to report the following transactions:
  • Transactions with a dollar value of less than $10;
  • Salary and benefits provided as part of employment;
  • Samples and educational materials;
  • Compensation for expert testimony;
  • And other exemptions.
The proposed regulations can be reviewed, in full, here. They are open for comment until April 5.

What Does This Mean Moving Forward?

It remains to be seen how many of the proposed regulations are ultimately passed. Under the HSPTA, drug and device companies operating in Ontario will be required to collect and disclose payment details starting in 2019. A searchable database of payment information is expected to be online in the fall of 2020. Any companies who recurrently refuse to follow their obligations under the HSPTA can face fines up to $100,000 for each day of non-compliance. We will continue to follow developments in this ongoing legislative change and will provide updates on how these changes may impact our clients as soon as more information is available. At Wise Health Law, we monitor trends and developments in health care and health law so that we can provide outstanding and forward-thinking legal advice to each of our clients. We regularly provide exceptional guidance on health law matters to regulated health professionals, regulated health professional associations, public hospitals, and other health-care organizations across the province. Contact us online, or at 416-915-4234 for a consultation.


Also in Blog

Cases to Watch: Marchi v. Nelson

by Mina Karabit September 22, 2020 3 min read

In August 2020, the Supreme Court heard and granted leave to appeal in Marchi v. Nelson, a case from the British Columbia Court of Appeal. The decision is one to watch as it will likely result in a renewed discussion of the distinction of policy versus operational decisions and their impacts on liability in tort law. The discussion will likely impact many of the anticipated post-COVID-19 lawsuits against public and government institutions.
Judicial Review: New Time Limits and a Helpful Primer

by Mina Karabit September 17, 2020 4 min read

In December 2019, Ontario’s Attorney General introduced Bill 161, the Smarter and Stronger Justice Act (the “Act”), which became law on July 8, 2020. The Act hopes to simplify a complex and outdated justice system by bringing changes to how legal aid services are delivered, how class actions are handled, and how court processes are administered.

Of note, the Act has amended the Judicial Review Procedures Act (JRPA) to establish new rules as to when an application for judicial review may be brought.

Any decisions made on or after July 8, 2020 are now subject to a 30-day limit for bringing an application for judicial review unless another Act provides otherwise. Courts, however, retain powers to extend the time for making an application for judicial review if satisfied that there are apparent grounds for relief and that no prejudice or hardship will be incurred by the delay. Before these amendments, the JRPA did not set out any time limits for bringing an application, but courts had powers to extend the time to bring an application if another Act prescribed the limit.

Recent Exemptions for Psychedelic Therapy in Canada

by Mina Karabit August 14, 2020 3 min read

In early August 2020, the Federal Minister of Health granted an exemption under the Controlled Drugs and Substances Act (CDSA) to four terminally ill Canadians to use psilocybin in their end of life care.

Psilocybin is one of the active ingredients/chemicals in “magic mushrooms,” the other is psilocin. Both psilocybin and psilocin are controlled substances under Schedule III of the CDSA. The sale, possession, production, etc. are prohibited unless authorized for clinical trial or research purposes under Part J of the Food and Drug Regulations. Both have been illegal in Canada since 1974. According to Health Canada, there are no approved therapeutic products containing psilocybin in Canada. However, the purified active ingredient, i.e. psilocybin, is being studied in supervised clinical settings for its potential to treat various conditions such as anxiety and depression.